<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00263016</url>
  </required_header>
  <id_info>
    <org_study_id>XRP6976B_2503</org_study_id>
    <nct_id>NCT00263016</nct_id>
  </id_info>
  <brief_title>Docetaxel in Non Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase II Pilot Study of Combination of Irinotecan and Cisplatin in Docetaxel/Cisplatin-Responsive Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To compare the tumour response rate of combination chemotherapy irinotecan/cisplatin&#xD;
           (IC) versus docetaxel/cisplatin (DC) in advanced NSCLC patients who responded to 3&#xD;
           courses of docetaxel/cisplatin.&#xD;
&#xD;
      Secondary Objectives :&#xD;
&#xD;
        -  To compare the time to progression after chemotherapy treatment between the IC and DC&#xD;
           arms of treatment.&#xD;
&#xD;
        -  To compare the toxicity profile of the IC and DC arms of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow recruitment&#xD;
  </why_stopped>
  <start_date>May 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumour response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival at 1 year</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven non-small cell lung carcinoma at first&#xD;
             diagnosis.&#xD;
&#xD;
          -  Stage IIIB or IV disease.&#xD;
&#xD;
          -  Tumour considered unresectable.&#xD;
&#xD;
          -  Performance status Karnofsky index &gt; 60% or WHO performance status &lt; or = 1.&#xD;
&#xD;
          -  Previous therapy&#xD;
&#xD;
               -  Chemotherapy: None.&#xD;
&#xD;
               -  Previous radiation therapy: prior irradiation for NSCLC is permitted, however,&#xD;
                  the measurable or evaluable non-measurable disease must be completely outside the&#xD;
                  radiation portal.&#xD;
&#xD;
          -  Laboratory requirements:&#xD;
&#xD;
               -  Hematology:&#xD;
&#xD;
                    -  Neutrophils ≥ 2.0 10^9/l,&#xD;
&#xD;
                    -  Platelets ≥ 100 10^9/l,&#xD;
&#xD;
                    -  Hemoglobin ≥ 10 g/dl.&#xD;
&#xD;
               -  Hepatic function:Total bilirubin &lt; 1 Upper Normal Limit (UNL), AST (SGOT) and ALT&#xD;
                  (SGPT) &lt; 2.5 UNL,Alkaline phosphatase &lt; 5 UNL ; except in presence of only bone&#xD;
                  metastasis and in absence of any liver disorders. Patients with AST and/or ALT &gt;&#xD;
                  1.5 x UNL associated with alkaline phosphatase &gt; 2.5 x UNL are not eligible for&#xD;
                  the study.&#xD;
&#xD;
               -  Renal function: Creatinine &lt; 140 µmol/l (1.6 mg/dl) ; if limit values, the&#xD;
                  calculated creatinine clearance should be &gt; 60 ml/min.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant, or lactating patients; patients of childbearing potential must implement&#xD;
             adequate contraceptive measures during study participation.&#xD;
&#xD;
          -  Known clinical brain or leptomeningeal involvement.&#xD;
&#xD;
          -  Pre-existing motor or sensory neurotoxicity of a severity &gt; grade 1 by National Cancer&#xD;
             Institute criteria.&#xD;
&#xD;
          -  Other serious illness or medical condition:&#xD;
&#xD;
               -  Congestive heart failure or unstable angina pectoris even if it is medically&#xD;
                  controlled. Previous history of myocardial infarction within 1 year from study&#xD;
                  entry, uncontrolled hypertension or high risk uncontrolled arrhythmias.&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorders including psychotic&#xD;
                  disorders, dementia or seizures that would prohibit the understanding and giving&#xD;
                  of informed consent.&#xD;
&#xD;
               -  Active uncontrolled infection.&#xD;
&#xD;
               -  Peptic ulcer, unstable diabetes mellitus or other contraindication for the use of&#xD;
                  corticosteroids.&#xD;
&#xD;
          -  Past or current history of neoplasm other than non-small cell lung cancer, except for&#xD;
             curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix.&#xD;
&#xD;
          -  Concurrent treatment with prednisone (or equivalent) except as use for the&#xD;
             prophylactic medication regimen, treatment of acute hypersensitivity reactions,&#xD;
             treatment of nausea / vomiting or unless chronic treatment (initiated &gt; 6 months prior&#xD;
             to study entry) at low dose (&lt; 20 mg methylprednisolone or equivalent).&#xD;
&#xD;
          -  Definite contraindications for the use of corticosteroids.&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs. Participation in another clinical&#xD;
             trial with any investigational drug within 30 days prior to study entry.&#xD;
&#xD;
          -  Concurrent treatment with any other anti-cancer therapy.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Iris CHAN, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>March 18, 2008</last_update_submitted>
  <last_update_submitted_qc>March 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

